Identifying Health Outcomes Associated with Changes in Use of Illicit Drugs (R01)

Post Date

May 11th 2012

Application Due Date

August 22nd 2012

Funding Opportunity Number

RFA-DA-13-007

CFDA Number(s)

93.279

Funding Instrument Type(s)

Grant

Funding Activity Categories

Education
Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Funding

• Estimated Total Funding:

  $3000000

• Award Range:

  $None - $500000

Grant Description

The National Institute on Drug Abuse (NIDA) is soliciting grant (R01) applications to test the hypothesis that reductions in illicit drug use are associated with improved health outcomes in patients. This FOA will support both prospective and retrospective studies, which may include, but not limited to, identification and characterization of beneficial health outcomes that are associated with reduced levels of drug use. Such studies may focus on identification and or validation of strategies, methods, and tools (including biomarkers) that can assess the salutary consequences resulting from reduced use of a particular illicit drug. These objectives may be achieved either by developing new or validating currently available methodologies that will monitor a health outcome associated with changes in use of a particular illicit drug. Further, identifying health outcomes associated with changes in drug use will stimulate translational research by providing additional measures of health effects linked to drug abuse, and may also be useful in evaluating the efficacy of new therapeutic agents for treating substance use disorders (SUDs). The ultimate goal of this FOA is to provide evidence that will enable regulatory authorities to accept reductions in illicit drug use as a valid outcome measure in clinical trials of pharmacotherapies for the treatment of SUDs.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-13-007.html